Kathy Schilling, MD, Boca Raton Regional Hospital, to
discuss how ProFound AI helped nine dedicated breast radiologists find 23% more
cancers, without increasing the rate of recalls
NASHUA, N.H., April 25, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced its “ProFound Insights, ProFound Impact” webinar series will feature Kathy
Schilling, MD, Medical Director, Christine E. Lynn Women’s Health &
Wellness Institute, Boca Raton Regional Hospital. The live event, titled “Elevating
Accuracy Across the Board at Boca Raton Regional Hospital” will take place on
Wednesday, May 24 at 10 am ET. The event will be moderated by iCAD’s President
and CEO, Dana Brown. To register, visit this link.
“ProFound AI is revolutionizing the way mammography is
performed, and with about two times the improvement in clinical performance
compared to leading competitors, this
leading-edge technology is making some of the country’s best radiologists even
better,” said Dana Brown, President and CEO of iCAD, inc. “We are delighted to
feature Dr. Schilling in this upcoming event and look forward to hearing her
share more of her clinical experience, best practices, and compelling case
studies demonstrating the unique workflow benefits our technology offers.”
During the event, Dr. Schilling will discuss the research
she recently presented
at the European Congress of Radiology (ECR) meeting demonstrating how ProFound
AI helped nine dedicated breast radiologists at the facility find 23% more
cancers, without increasing the rate of recalls. She will also present a live
clinical case review showcasing how ProFound AI can enhance cancer detection in
a clinical setting.
“ProFound AI improved the performance of all nine
dedicated breast radiologists, across the board. We read mammography every day,
with decades of experience combined – we thought we were pretty good at it. But
we were surprised to learn that ProFound AI made us even better,” said Dr.
Schilling. “Now that I’ve seen the measurable improvements this technology offers,
both to our team and our patients, I’ll never read another mammogram without
ProFound AI became the first technology of its kind to be
FDA cleared in 2018. Built with the latest in deep-learning artificial
intelligence, ProFound AI is clinically proven to improve radiologists’
sensitivity by 8%, reduce the rate of false positives and unnecessary callbacks
by 7%, and slash reading time by more than half.
The “ProFound Insights, ProFound Impact” webinar series launched
last year, and has featured a number of distinguished clinical, IT and
administrative experts, along with customer success stories and impactful case
studies from facilities worldwide. Previous event recordings are available on
the Company’s website, www.icadmed.com.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD® is a global medical
technology leader providing innovative cancer detection and therapy solutions.
For more information, visit www.icadmed.com.
Certain statements contained in this News Release
constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements about the
expansion of access to the Company’s products, improvement of performance,
acceleration of adoption, expected benefits of ProFound AI®, the benefits of
the Company’s products, and future prospects for the Company’s technology
platforms and products. Such forward-looking statements involve a number of
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance, or achievements of the Company to be materially
different from any future results, performance, or achievements expressed or
implied by such forward-looking statements. Such factors include, but are not
limited, to the Company’s ability to achieve business and strategic objectives,
the willingness of patients to undergo mammography screening in light of risks
of potential exposure to Covid-19, whether mammography screening will be
treated as an essential procedure, whether ProFound AI will improve reading
efficiency, improve specificity and sensitivity, reduce false positives and
otherwise prove to be more beneficial for patients and clinicians, the impact
of supply and manufacturing constraints or difficulties on our ability to
fulfill our orders, uncertainty of future sales levels, to defend itself in
litigation matters, protection of patents and other proprietary rights, product
market acceptance, possible technological obsolescence of products, increased
competition, government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt obligations,
competitive factors, the effects of a decline in the economy or markets served
by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,” “demonstrate,”
“intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,”
“seek,” and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website at
http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Jessica Burns, iCAD
Accessed 1-19-22. FDA 510K
submissions K182373, K201019, K193229
 Conant, E et al. (2019).
Improving Accuracy and Efficiency with Concurrent Use of Artificial
Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial
Intelligence. 1 (4). Accessed via